Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05805891
• Other study ID #: Bortezomib-RA
• Status: Recruiting
• Phase: N/A
• Start date: December 2023
• Est. completion date: December 2025

Study information

• Verified date: March 2023
• Source: Chinese SLE Treatment And Research Group
• Contact: Xinping Tian, MD
• Phone: 86-13691165939
• Email: tianxp6[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, single-arm, prospective study on the efficacy and safety of Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age between 18~70 years.

2. Fulfilling the 2010 ACR/EULAR classification criteria for RA.

3. Failed to at least two bDMARDs (including but not limited to TNF inhibitors, IL-6 receptor inhibitors, T cell costimulation inhibitor and anti-B cell biologics) or tsDMARDs (including but not limited to JAK inhibitors) in combination with a csDMARD for at least 12 weeks. The dosage of cs/b/tsDMARDs needs to be stable for at least 6 weeks.

4. For patients receiving glucocorticoids, the dosage of GC needs to be less than or equal to 10mg prednisone equivalent and stable for at least 6 weeks.

5. For patients receiving non-steroid anti-inflammatory drugs, the dosage of NSAID needs to be stable for at least 2 weeks.

6. Neutrophil=1.0×10^9/L, platelet=100×10^9/L, alanine transaminase (ALT) and aspartate aminotransferase (AST) within 3 ULN, total bilirubin within 1.5 ULN.

7. Informed consent obtained.

Exclusion Criteria:

1. Other concomitant autoimmune diseases (except for Sjogren's syndrome secondary to rheumatoid arthritis).

2. The presence of severe uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neuropsychiatric disorders, or abnormal laboratory tests. The investigators consider that participation in the study may make unacceptable risks to the subjects.

3. A history of malignancy with a clinical cure time of less than 5 years.

4. Pregnant or breast-feeding women, or planning to get pregnant or start breastfeeding during the study.

5. Vaccinated with live attenuated virus within 4 weeks before entering the study.

6. Allergic to bortezomib or mannitol.

7. Participated in any other investigational drug trial within 12 weeks before study initiation.

8. Active hepatitis or liver disease at the time of screening: Hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibodies (HCVAb) positive; (Note: If Hepatitis B Core Antibody, (HBcAb) is positive and HBsAg is negative, HBV-DNA detection will be performed, patient is eligible if HBV-DNA was negative).

9. Active herpes zoster infection, or severe infection requiring intravenous antibiotics or hospitalization occurred 12 weeks before study initiation.

10. Other conditions that not suitable for inclusion in the study, assessed by the investigators.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• bortezomib
bortezomib 2mg/week subcutaneous injection

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese SLE Treatment And Research Group

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DAS28 remission or LDA at week 24	Proportion of patients who achieve remission or low disease activity (LDA) at week 24 according to DAS 28.	24 weeks
Secondary	DAS28 improvement at week 12	Proportion of patients who achieve remission or low disease activity at week 12 according to DAS 28. Proportion of patients who achieve at least a 50% reduction of DAS28 at week 12.	12 weeks
Secondary	SDAI improvement at week 12 and remission or LDA at week 24	Proportions of patients who achieve remission or low disease activity at week 12 and week 24 according to SDAI. Proportion of patients who achieve at least a 50% reduction of SDAI at week 12.	24 weeks
Secondary	CDAI improvement at week 12 and remission or LDA at week 24	Proportions of patients who achieve remission or low disease activity at week 12 and week 24 according to CDAI. Proportion of patients who achieve at least a 50% reduction of CDAI at week 12.	24 weeks
Secondary	ACR20, ACR50 and ACR70 at week 12 and week 24	Proportions of patients who achieve ACR20, ACR50 and ACR70 at week 12 and week 24.	24 weeks
Secondary	Changes in glucocorticoid dose	Changes in glucocorticoid dose at week 12 and 24 from baseline.	24 weeks
Secondary	Adverse events during the study	All adverse events, severe adverse events and proportion of patients who discontinued bortezomib due to adverse events from the first dose of bortezomib to 4 weeks after the last dose.	28 weeks